{"id":98592,"date":"2022-03-18T16:00:00","date_gmt":"2022-03-18T20:00:00","guid":{"rendered":"https:\/\/hispanicprwire.com\/english-pritzker-levine-llp-robbins-geller-rudman-dowd-llp-sharp-law-llp-burns-charest-llp-and-keller-rohrback-l-l-p-announce-a-class-action-settlement-with-mylan-for-purchasers-of-epipe\/"},"modified":"2022-03-18T16:10:06","modified_gmt":"2022-03-18T20:10:06","slug":"pritzker-levine-llp-robbins-geller-rudman-dowd-llp-sharp-law-llp-burns-charest-llp-y-keller-rohrback-l-l-p-anuncian-un-acuerdo-de-conciliacion-de-demanda-colectiva-con-mylan-para-compradore","status":"publish","type":"post","link":"https:\/\/hispanicprwire.com\/en\/pritzker-levine-llp-robbins-geller-rudman-dowd-llp-sharp-law-llp-burns-charest-llp-y-keller-rohrback-l-l-p-anuncian-un-acuerdo-de-conciliacion-de-demanda-colectiva-con-mylan-para-compradore\/","title":{"rendered":"Pritzker Levine LLP, Robbins Geller Rudman &amp; Dowd LLP, Sharp Law, LLP, Burns Charest LLP and Keller Rohrback L.L.P., Announce a Class Action Settlement with Mylan for Purchasers of EpiPen\u00ae, EpiPen Jr\u00ae and\/or their Authorized Generics"},"content":{"rendered":"<p><\/p>\n<style type=\"text\/css\"><![CDATA[\n\/* Style Definitions *\/\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n]]><\/style>\n<div class=\"xn-content\">\n<p><span class=\"xn-location\">KANSAS CITY, Kan.<\/span>, <span class=\"xn-chron\">March 18, 2022<\/span> \/PRNewswire-HISPANIC PR WIRE\/ &#8212; <\/p>\n<p class=\"prntac\"><b>EpiPen\u00ae (&#8220;EpiPen&#8221;) Auto-Injector Class Action <br \/><\/b><b>Settlement with Mylan for <span class=\"xn-money\">$264 Million<\/span><\/b><\/p>\n<p class=\"prntac\"><i>In re\u00a0EPIPEN (EPINEPHRINE INJECTION, USP) MARKETING, <br \/><\/i><i>SALES PRACTICES and antitrust Litigation<br \/><\/i>Case No. 2:17-md-02785-DDC-TJJ, MDL 2785 (District of <span class=\"xn-location\">Kansas<\/span>)<\/p>\n<p class=\"prntac\"><b>To register to receive compensation, visit <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3477482-1&amp;h=4212148179&amp;u=http%3A%2F%2Fwww.epipenclassaction.com%2F&amp;a=www.EpiPenClassAction.com\" rel=\"nofollow\">www.EpiPenClassAction.com<\/a><\/b><\/p>\n<p class=\"prntac\"><b>Who Is Eligible?<\/b><\/p>\n<p>People or entities that paid for some or all of the purchase price of a branded or authorized generic EpiPen\u00ae or EpiPen Jr\u00ae for the purpose of consumption, and not resale.\u00a0 This includes:<\/p>\n<ul type=\"disc\">\n<li>Yourself <\/li>\n<li>Family members <\/li>\n<li>Plan participants or employees<\/li>\n<\/ul>\n<p>This lawsuit asserts that Defendants violated certain state antitrust, federal racketeering, and other laws, harming competition and causing class members to overpay for EpiPen products. Defendants deny these allegations.<\/p>\n<p><b>PLEASE NOTE:\u00a0 This is NOT a recall, safety, or other similar notice. No one is claiming that EpiPen products are unsafe or ineffective.<\/b>\u00a0<\/p>\n<p><b>If you purchased or paid for an EpiPen\u00ae or EpiPen Jr\u00ae Auto-Injector at any time between <span class=\"xn-chron\">August 24, 2011<\/span> and <span class=\"xn-chron\">November 1, 2020<\/span>, your rights may be affected by this class action settlement with Mylan. <\/b><\/p>\n<p>If you fall into one of these categories you are a Class Member (unless you are excluded by the class definition, available on the settlement website) and you may:<\/p>\n<ol type=\"1\">\n<li>Share in the distribution of settlement funds OR <\/li>\n<li>Object. Any objection to the Settlement, the Plan of Allocation, or the fee and expense application must be filed with the Court and sent to and received by counsel for the parties <b>no later than <\/b><b><span class=\"xn-chron\">June 8, 2022<\/span><\/b>:<\/li>\n<\/ol>\n<p class=\"prntac\">Clerk of the Court<br \/><span class=\"xn-location\">United States<\/span> District Court, District of <span class=\"xn-location\">Kansas<\/span><br \/>500 State Avenue<br \/><span class=\"xn-location\">Kansas City<\/span>, KS\u00a0 66101<br \/><span class=\"xn-person\">Rex A. Sharp<\/span><br \/>SHARP LAW, LLP<br \/>4820 West\u00a075th Street<br \/><span class=\"xn-location\">Prairie Village<\/span>, KS\u00a0 66208<\/p>\n<p class=\"prntac\"><span class=\"xn-person\">Adam K. Levin<\/span><br \/>HOGAN LOVELLS US LLP<br \/>555 13th Street, NW<br \/><span class=\"xn-location\">Washington, DC<\/span> 20004<\/p>\n<p>If you are a Class Member and did not timely request exclusion prior to <span class=\"xn-chron\">January 15, 2021<\/span>, you will be bound by any judgment in the Action. You may appear in court through an attorney at your expense. The Court will hold a hearing on <span class=\"xn-chron\">July 6, 2022<\/span>, at <span class=\"xn-chron\">9:30 a.m. Central Time<\/span> to consider whether to approve the Settlement, attorneys&#8217; fees, expenses, and service awards.<\/p>\n<p>To share in the distribution of the Net Settlement Fund, Class Members who did not already submit a Proof of Claim form as part of the settlement in this case with the Pfizer Defendants in 2021 must submit a Proof of Claim through the settlement website or by mail. If submitted through the settlement website, the Proof of Claim must be <b>received no later than <span class=\"xn-chron\">July 25, 2022<\/span><\/b>. If submitted by mail, the Proof of Claim must be <b>postmarked no later than <span class=\"xn-chron\">July 25, 2022<\/span><\/b>. Unless the deadline is extended, failure to submit your timely Proof of Claim will preclude you from receiving any payment from the Settlement. <b>If you previously submitted a Proof of Claim in this case in 2021 as part of the settlement with Pfizer, you do not need to submit a second Proof of Claim and your Proof of Claim will apply to both settlements.<\/b><\/p>\n<p>For more information about how to participate in this proposed class action settlement\u00a0with Mylan, please visit <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3477482-1&amp;h=4212148179&amp;u=http%3A%2F%2Fwww.epipenclassaction.com%2F&amp;a=www.EpiPenClassAction.com\" rel=\"nofollow\">www.EpiPenClassAction.com<\/a>, call 1\u2010877-221-7632, or write to:<\/p>\n<p class=\"prntac\">EpiPen Settlement<br \/>c\/o A.B. Data, Ltd.<br \/>P.O. Box 173113<br \/><span class=\"xn-location\">Milwaukee, WI<\/span> 53217<\/p>\n<p><span class=\"xn-chron\">March 18, 2022<\/span><\/p>\n<p>SOURCE  Pritzker Levine LLP, Robbins Geller Rudman &amp; Dowd LLP, Sharp Law, LLP, Burns Charest LLP and Keller Rohrback L.L.P.<\/p>\n<\/div>\n<p><\/p>","protected":false},"excerpt":{"rendered":"<div class=\"xn-content\">\n<p><span class=\"xn-location\">KANSAS CITY, Kan.<\/span>, <span class=\"xn-chron\">March 18, 2022<\/span> \/PRNewswire-HISPANIC PR WIRE\/ &#8212; <\/p>\n<p class=\"prntac\"><b>EpiPen\u00ae (&#8220;EpiPen&#8221;) Auto-Injector Class Action <br \/><\/b><b>Settlement with Mylan for <span class=\"xn-money\">$264 Million<\/span><\/b><\/p>\n<p class=\"prntac\"><i>In re\u00a0EPIPEN (EPINEPHRINE INJECTION, USP) MARKETING, <br \/><\/i><i>SALES PRACTICES and antitrust Litigation<br \/><\/i>Case No. 2:17-md-02785-DDC-TJJ, MDL 2785 (District of <span class=\"xn-location\">Kansas<\/span>)<\/p>\n<p class=\"prntac\"><b>To register to&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-98592","post","type-post","status-publish","format-standard","hentry","category-negocios-y-finanzas"],"acf":[],"_links":{"self":[{"href":"https:\/\/hispanicprwire.com\/en\/wp-json\/wp\/v2\/posts\/98592","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/hispanicprwire.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/hispanicprwire.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/hispanicprwire.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/hispanicprwire.com\/en\/wp-json\/wp\/v2\/comments?post=98592"}],"version-history":[{"count":"1","href":"https:\/\/hispanicprwire.com\/en\/wp-json\/wp\/v2\/posts\/98592\/revisions"}],"predecessor-version":[{"id":98593,"href":"https:\/\/hispanicprwire.com\/en\/wp-json\/wp\/v2\/posts\/98592\/revisions\/98593"}],"wp:attachment":[{"href":"https:\/\/hispanicprwire.com\/en\/wp-json\/wp\/v2\/media?parent=98592"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/hispanicprwire.com\/en\/wp-json\/wp\/v2\/categories?post=98592"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/hispanicprwire.com\/en\/wp-json\/wp\/v2\/tags?post=98592"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}